Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children

被引:27
作者
Tran, A
VauzelleKervroedan, F
Rey, E
Pons, G
dAthis, P
Chiron, C
Dulac, O
Renard, F
Olive, G
机构
[1] UNIV PARIS 05,HOP ST VINCENT DE PAUL,F-75014 PARIS,FRANCE
[2] LAB BIOCODEX,F-60200 COMPIEGNE,FRANCE
关键词
stiripentol; carbamazepine; epilepsia; drug metabolism; antiepileptic drugs; children;
D O I
10.1007/s002280050147
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To study the relationship between the plasma concentration of stiripentol (STP), a new antiepileptic drug, and its inhibitory effect on the formation of carbamazepine epoxide (CBZE) in epileptic children treated with carbamazepine (CBZ) either alone or in combination with another antiepileptic drug. Methods: Minimum plasma concentration of antiepileptic drugs was measured before initiation of STP therapy (day 0) and oil days 28 (STP 60 mg . kg(-1) . day(-1)) and 54 (STP 90 mg . kg(-1) day(-1)) by HPLC, Results: The CBZE/CBZ plasma concentration ratio decreased exponentially with increasing minimum plasma STP concentration (r = 0.80), The asymptote of the curve allowed the calculation of the minimum plasma STP concentration required to obtain the maximum inhibitory effect, i,e. 6.7 mg . l(-1). Conclusion: The inhibitory effect of STP on CBZ metabolism expressed as the CBZE/CBZ plasma concentration ratio is dependent on STP plasma concentration, with a maximum effect at an average of 7 mg . l(-1) The present data suggest that in order to evaluate the anticonvulsant efficacy of STP as add-on therapy, the minimum plasma STP concentration should be maintained above 7 mg . l(-1) and the dosage of CBZ should simultaneously be decreased in steps by more than 50% to minimize the change in CBZ plasma concentration.
引用
收藏
页码:497 / 500
页数:4
相关论文
共 11 条
[1]   CARBAMAZEPINE DOSE REQUIREMENTS DURING STIRIPENTOL THERAPY - INFLUENCE OF CYTOCHROME-P-450 INHIBITION BY STIRIPENTOL [J].
KERR, BM ;
MARTINEZLAGE, JM ;
VITERI, C ;
TOR, J ;
EDDY, AC ;
LEVY, RH .
EPILEPSIA, 1991, 32 (02) :267-274
[2]   AUTOINDUCTION AND STEADY-STATE PHARMACOKINETICS OF CARBAMAZEPINE AND ITS MAJOR METABOLITES [J].
KUDRIAKOVA, TB ;
SIROTA, LA ;
ROZOVA, GI ;
GORKOV, VA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (06) :611-615
[3]  
Levy Rene H., 1993, Epilepsia, V34, P69
[4]   STIRIPENTOL KINETICS IN EPILEPSY - NONLINEARITY AND INTERACTIONS [J].
LEVY, RH ;
LOISEAU, P ;
GUYOT, M ;
BLEHAUT, HM ;
TOR, J ;
MORELAND, TA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) :661-669
[5]  
LEVY RH, 1985, EPILEPSIA, V26, P544
[6]  
LEVY RH, 1987, 17 EP INT C JER ISR
[7]   A COMPREHENSIVE STUDY OF THE RELATION BETWEEN SERUM CONCENTRATIONS, CONCENTRATION RATIOS, AND LEVEL/DOSE RATIOS OF CARBAMAZEPINE AND ITS METABOLITES WITH AGE, WEIGHT, DOSE, AND CLEARANCES IN EPILEPTIC CHILDREN [J].
LIU, H ;
DELGADO, MR .
EPILEPSIA, 1994, 35 (06) :1221-1229
[8]  
LOISEAU P, 1989, ANTIEPILEPTIC DRUG I, P129
[9]   INVITRO INHIBITION BY STRIPENTOL OF RAT-BRAIN CYTOCHROME-P-450-MEDIATED NAPHTHALENE HYDROXYLATION [J].
MESNIL, M ;
TESTA, B ;
JENNER, P .
XENOBIOTICA, 1988, 18 (09) :1097-1106
[10]   EXVIVO INHIBITION OF RAT-BRAIN CYTOCHROME-P-450 ACTIVITY BY STIRIPENTOL [J].
MESNIL, M ;
TESTA, B ;
JENNER, P .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (19) :3619-3622